HELLO CHINA

INDUSTRY CLUSTER · Biomedicine

Anguo Chinese medicinal material processing

Anguo processing is not simply slicing herbs traded in the market. It converts natural variation into releasable pharmaceutical materials, decoction pieces or foods with a clearly defined licence boundary. A local survey published by the National Bureau of Statistics in 2026 reported RMB 89.756 billion in 2024 revenue for Anguo's modern Chinese medicine sector, 99 above-scale pharmaceutical manufacturers and 119 GMP-certified decoction-piece producers. Regional size cannot replace batch evidence for origin, testing, processing, labelling and release, and medicines, health foods and ordinary foods require different compliance judgements.

Formation and regional foundations

When roots, flowers or fruits enter a plant, they are first separated by source, botanical identity, appearance and moisture before cleaning, cutting, steaming, stir-processing or extraction is chosen. Testing considers assay together with pesticide residues, heavy metals, mycotoxins, sulphur dioxide and microbiological risks according to the material and intended use. A pharmaceutical batch closes through records, deviation handling and authorised quality release; a medicinal-food product returns instead to food licensing, permitted ingredients, formulation and label. Anguo brings raw material, testing, processing and trade together, but every change of intended use requires a fresh regulatory decision.

A herb does not become compliant merely by entering an industrial park. The same named material can vary in botanical origin, place, harvest, drying and storage, changing assay, moisture, pesticide residue or mould risk. A plant must first define intended use, then arrange identification, cleaning, processing, extraction and packing under the pharmacopoeia, an approved process or food rules. Anguo shortens the distance among trade, cultivation, testing and manufacture, but the quality decision still belongs to a named entity, site, material and batch.

Core geography: A quality-controlled network linking Anguo Modern Chinese Medicine Industrial Park, the Digital Chinese Medicine Market and surrounding standardised cultivation bases through herb identification, primary processing, decoction pieces, extraction, formula granules, proprietary medicines and medicinal-food products

Responsibility route for one herb lot

Intended use precedes processing; release follows review

Nodes show where procurement and quality decisions occur, not a mandatory factory layout.

  • Use and standard desk — Fixes medicine, health-food or ordinary-food status, material, grade and responsible entity.
  • Cultivation and traded lot — Retains origin, species, harvest, primary processing, supplier, transport and storage information.
  • Receipt, identity and grading — Quarantines material, reviews documents, appearance, foreign matter and moisture, and defines sampling.
  • Cleaning, processing and extraction — Controls critical conditions for cutting, steaming, stir-processing, drying or extraction and concentration.
  • Laboratory and batch review — Reviews identity, assay, contaminants, process deviations and packing records together.
  • Release and channel traceability — Authorises release by product status and links label, customer, logistics, retention sample and recall path.

01 · Define the product before the process

One herb may enter medicines, health foods or ordinary foods, but approvals, ingredients and labels do not merge under a commercial name.

Anguo is recognised as a medicinal-material processing cluster, while Baoding's industry profile counts pharmaceutical production, health foods and ordinary medicinal foods separately. That separation sets the due-diligence starting point: define the target product's regulatory status, then examine the manufacturing entity and site, rather than beginning with whether a familiar brand sells something that looks similar.

A pharmaceutical decoction piece must fit a drug-manufacturing scope, pharmacopoeial or approved standard and quality release. A health food also requires its registration or filing, permitted function and dedicated mark. Ordinary foods such as substitute teas and solid drinks are governed by food category, permitted ingredients and labelling. They may share cleaning, cutting or packing equipment, but that does not give them common claims or acceptance evidence.

A request for quotation should place intended use, standard, grade, pack and sales territory immediately after the product name. If a supplier answers only with 'industrial-park product' or 'medicinal and edible', the buyer still needs the full legal entity, manufacturing address, licence number and confirmation that the named item falls within scope. Those details sit closer to delivery responsibility than park images or brand stories.

  • Product status determines the compliance route.
  • A brand does not replace the manufacturing entity.
  • Shared equipment does not create shared claims.

02 · Origin is more than a place name

Botanical identity, plot, harvest, primary processing and storage define incoming material; the market is only a trading entry point.

Hebei's industry authority records more than thirty medicinal crops grown regularly in Anguo, supported by standardised bases and seed propagation, while the city also functions as a national trading hub. Procurement records must distinguish traded in Anguo, processed in Anguo and grown in Anguo. The three can overlap, but they can also refer to entirely different places.

One Chinese material name may cover different botanical sources or plant parts, while growing area changes appearance and assay. Before receipt, supplier, cultivation or collection place, harvest period, drying, sulphur treatment, pack and transport records should be tied to the lot number. If lots are mixed, an average laboratory result should not hide origin differences.

A recognised regional name or geographical indication can establish a place and reputation, but it is not an automatic pass for every contaminant and assay. Buyers can request field-input records, origin tests, supplier audits and retained samples, adding authenticity or fingerprint work according to material risk. Origin evidence and finished-material testing should complement rather than replace one another.

  • Trading, processing and growing locations are separate facts.
  • Origin records attach to the lot.
  • Geographical reputation does not replace testing.

03 · Quarantine before cutting

Delivered weight is not usable weight; foreign matter, moisture, infestation and mould change yield and risk.

Incoming material should remain in quarantine until pack identity, supplier records and physical goods agree, without mixing into released inventory. Sampling must consider bag count, positions and heterogeneity, especially large root packs, compressed flowers or hygroscopic powdery materials. A handful from the surface cannot represent the lot.

Cleaning removes soil, non-medicinal parts and foreign matter, while cutting changes slice thickness, drying rate and later extraction. Excess washing can remove soluble constituents, insufficient moistening causes breakage, and incomplete drying invites microbial or mould risk. Parameters therefore respond to the material and incoming state instead of following one schedule for every herb.

Acceptance can specify clean-material yield, shape, thickness, moisture, fines and foreign matter, with supplier explanation for unusual yield. A gross-weight contract turns soil and excess moisture into purchasing loss. Driving moisture as low as possible can also create breakage or alter later processing, so a justified range is better than a one-way target.

  • Quarantined material remains separated.
  • Sampling covers within-lot variation.
  • Clean-material yield belongs in the contract.

04 · Processing changes more than appearance

Heat, excipients, time and solvent change composition and use; deviations return to the approved route for judgement.

Drug-manufacturing information lists cleaning, cutting, stir-processing, adjuvant processing, steaming, boiling, fermentation and water trituration separately because each has different controls. Degree of heating, excipient quantity, penetration of steam or boil and fermentation state affect appearance, assay and safety. The phrase 'traditional processing' cannot replace temperature, time, charge and operator records.

Extraction converts solid material into solution, concentrate or dry powder and controls material lot, solvent ratio, temperature, time, filtration, concentration endpoint and yield. Formula granules also require a defined relationship from decoction piece through reference decoction to granule and adequate specificity. An extract for a proprietary medicine must enter the approved formula and process rather than being substituted as a generic concentrate.

Process transfer should document equipment differences among laboratory, pilot and commercial batches, blend uniformity, cleaning validation and hold times. In contract processing, the buyer should define material ownership, loss calculation, deviation approval, rework limits and ownership of samples and data. Agreeing only a fee per kilogram leaves the most important quality decisions outside the contract.

  • Each processing method has distinct controls.
  • Extraction yield needs an explanation.
  • The contract allocates quality decisions.

05 · The laboratory must answer for this lot

An instrument list is not testing capability; method suitability, sampling and atypical-result handling determine whether a report supports release.

Public information for Tong Ren Tang's Anguo decoction-piece operation lists liquid and gas chromatography, atomic absorption and thin-layer chromatography for assay, pesticide residue, heavy metals and aflatoxins. Real capability also includes suitable sample preparation, reference standards, calibration, method verification, system suitability and trained analysts. A procurement audit should trace one raw record through to the final report.

Natural materials often produce results near a limit or with substantial within-lot variation. The laboratory should define retesting, resampling, out-of-specification and atypical-trend handling before results are known, rather than adding tests after an unfavourable number appears. An external laboratory can add specialist capability, but the client still confirms sample identity, sealed transport, method version and report-to-lot linkage.

Release is not an automatic step after a laboratory report is stamped. Quality review also covers supplier status, manufacturing record, environment and cleaning, deviations, yield, packaging materials, label and stability commitments, confirming that changes were approved. Direct-use pieces, toxic materials and contamination-prone herbs call for deeper record closure and oversight as risk rises.

  • Trace raw data to the report.
  • The exception procedure precedes the result.
  • Batch review extends beyond testing.

06 · Traceability must lead back to the source

A scan display matters only when coding, physical movement and responsibility records agree.

An earlier Hebei industry profile recorded 21 cultivation bases, 93 decoction-piece producers, traders and pharmacies, and 1,350 merchants in Anguo's traceability system. That scale shows an ability to connect participants, not completeness for every lot. On site, select a finished pack at random and trace its raw-material lot, supplier, tests, processing, packing and destination.

The Sinopharm Lerentang Anguo case shows that equipment and industrial-internet upgrades can increase packing efficiency, reduce water use and improve process consistency. Those gains evaluate a specific project and should not be projected across every workshop or product. Buyers should instead inspect whether electronic records preserve audit trails, access rights, timestamps, master-data versions and reasons for manual changes.

A mock recall directly tests whether traceability works. Within a defined time, the firm should locate stock, customers, transport and related raw material for the target lot and explain the effect of blending, rework and shared-line products. A QR page without quantity reconciliation and responsible contacts remains a display rather than operational traceability.

  • Random backward tracing beats a prepared demo.
  • Upgrade data stays within its project scope.
  • A recall needs quantity reconciliation.

07 · Three firms, three different capabilities

Group background, manufacturing scope and product route differ; each company assessment must reach the entity, site and process.

Tong Ren Tang has a medicinal-material processing entity, a decoction-piece entity and group-shared preprocessing sites in Anguo. A listed-company filing describes the processing company as an intermediate step for later proprietary-medicine production and gives designed capacities, while a current Beijing licence lists Anguo preprocessing locations on Qianjin Road and Xueyuan Street. A contract should match its named entity and address rather than merging all of them into one 'Tong Ren Tang Anguo factory'.

Public licence information for Sinopharm Lerentang Hebei Pharmaceutical covers ordinary, direct-use and toxic decoction pieces at two addresses, Nos. 33 and 66 Qianjin Road. A Hebei industry case also shows cleaning, packing and digital workshop improvements. Together they support a decoction-piece manufacturing assessment, but formula granules, extracts or foods would need separate evidence for the relevant scope.

Regulatory information locates Hebei Qixin at No. 28 Baoheng South Road and lists cleaning, cutting, stir-processing, steaming, boiling and fermentation for decoction pieces. Although 'granule' appears in the company name, that does not establish every formula-granule capability. Product name, licence classification and order specification need separate checks, including whether the public licence snapshot remains current.

  • Group entities must not be merged.
  • Decoction-piece capability does not imply granules.
  • A company name is not a licence scope.

08 · Turn due diligence into one deliverable lot

A good order converts regional strength into acceptable origin, quality, time and responsibility.

Anguo's 99 above-scale pharmaceutical firms, 119 decoction-piece producers and large sector revenue show abundant choice, which also means wide variation in capability. A shortlist should be built around the target material: who holds the relevant scope, who secures stable supply, who performs critical tests, and who owns deviations and recall. Firm counts alone answer none of those questions.

Sample evaluation should use material and commercial processing equivalent to the intended purchase, not a showroom selection. Parties can pre-agree identity, assay, contaminants, clean yield, slice and moisture, pack integrity, transport conditions, lead time and nonconformance handling. Continuous supply adds seasonal change, approval of alternative origins and safety stock.

The final file should retain contract version, supplier qualification, raw and finished lot numbers, test reports, processing-record summary, deviations and changes, release document, logistics and complaint contacts. A repeat order should not simply copy the previous one; it should check changes in licences, pharmacopoeial standards, origin market and company status. Anguo's market moves quickly, and purchasing control must keep pace.

  • Build the shortlist around the target material.
  • The sample matches commercial processing.
  • Repeat orders refresh dated evidence.

Sources and reading notes

The unit of judgement is a batch task with a defined intended use. A buyer fixes species, botanical origin, place and harvest requirements, then confirms medicine or food status, applicable standard, tests, processing method, pack and release responsibility. Sector revenue, firm counts and market trade show regional capacity; they do not prove that one supplier holds the required scope, and an old certificate, group brand or park presence cannot stand in for a current manufacturing approval.

  • Anguo's modern Chinese medicine sector reported 2024 revenue of RMB 89.756 billion.
  • The same survey reported 99 above-scale pharmaceutical manufacturers.
  • It recorded 119 GMP-certified decoction-piece producers.
  • A 2026 local profile listed 38 high-technology firms and 41 specialised and sophisticated firms in the cluster.

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

  • Beijing Tong Ren Tang (Anguo) Medicinal Materials Processing Co., Ltd. — The company cleans, cuts and processes medicinal materials in Anguo as an upstream step for later Tong Ren Tang proprietary-medicine production. Project review should distinguish the Anguo processing entity, the separate decoction-piece company and group-shared preprocessing sites, matching contract entity, manufacturing address, target material, charge and delivery records one by one.
  • Hebei Qixin Chinese Medicine Granule and Decoction Piece Co., Ltd. — Hebei Qixin manufactures decoction pieces on Baoheng South Road using published cleaning, cutting, stir-processing, calcining, charring, steaming, boiling, scalding, stewing, fermentation, germination and adjuvant processing. Medical-insurance and public-procurement records show its products in cross-regional purchasing; an order still confirms the current licence, item, origin, processed grade and batch tests.
  • Sinopharm Lerentang Hebei Pharmaceutical Co., Ltd. — Sinopharm Lerentang Hebei Pharmaceutical manufactures ordinary, direct-use and toxic decoction pieces in Anguo through cleaning, cutting, stir-processing, steaming, boiling and fermentation. A public digital case describes upgrades in cleaning and packing; each order must still define material, processing method, pack, batch release and the applicable one of its two sites.
  • Request a company-record correction or removal — Requests are reviewed by a person, handled promptly after verification, free of charge and not tied to commercial cooperation.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.